Compare Recursion Pharmaceuticals Inc (RXRX) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs SoundHound AI Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while SoundHound AI Inc trades at $6.55 (market cap $2.75B). The key difference: SoundHound AI Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| RXRX | SOUN | |
|---|---|---|
Market Cap | $1.53B | $2.75B |
Sector | Health | Technology |
52-Week High | $6.79 | $21.40 |
52-Week Low | $2.84 | $5.90 |
Enterprise Value | $946.50M | $2.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
SoundHound AI (SOUN) trades at $6.31, up 0.64% today, but remains down 37% year-to-date. The stock shows a bearish technical trend with neutral oscillators. Fundamentally, revenue grew to $168.92 million in 2025, but net losses widened to -$14.01 million. Recent news highlights its leadership in conversational AI, yet concerns over cash burn persist. Analyst consensus is bullish with a $13.00 price target, indicating significant potential upside from current levels.
Outlook: High growth potential in voice AI markets contrasts with persistent losses and negative cash flow. Investment opportunity lies in market expansion and acquisitions, but risks include execution challenges and sustained cash burn. Investors should weigh the bullish analyst targets against the company's current unprofitability and high valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
